Amphastar Pharmaceuticals, Inc. AMPH
Regular-session close
After hours · Nov 19, 4:01 PM ET
- YTD
- +4.97%
- 1 year
- +10.80%
5D -1.03 (-3.53%)
- Market cap
- 1.20B
- Revenue (ttm)
- 745.79M
- Profit margin
- 13.27%
- EPS (ttm)
- 2.18
- Shares out
- 42.65M
- P/E ratio
- 12.89
- Forward P/E
- 8.38
- YTD return
- +4.97%
- 1-year return
- +10.80%
- 50-day average
- 26.33
- Volume
- 662.51K
- Avg volume
- 468.40K
- Open
- 29.36
- Previous close
- 29.71
- Day's range
- 27.95 – 29.56
- 52-week range
- 16.65 – 31.00
- Beta
- 0.94
- Analysts
- Hold
- Price target
- 24.50 (-12.8%)
- Earnings date
- Feb 25, 2027
Key statistics
- 200-day average
- 22.38
- Enterprise value
- 1.73B
- Price / sales
- 1.61
- Price / book
- 1.47
- Revenue growth
- 8.20%
- Free cash flow
- 9.20M
- Total cash
- 230.63M
- Total debt
- 691.69M
- Return on equity
- 12.44%
- Short % of float
- 21.71%
Fundamental scorecard
15 of 25 checks passed on AMPH’s reported financials
15of 25 checks passed
- Value 5 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 20.00
- Target (mean)
- 24.50
- Target (high)
- 30.00
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell1
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.78763.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.787 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.859 | 1.14 | +0.28 | +32.71% |
| Aug 6, 2026 | Jun 30, 2026 | 0.62 | 0.91 | +0.29 | +46.77% |
| May 7, 2026 | Mar 31, 2026 | 0.70 | 0.42 | -0.28 | -40.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.903 | 0.73 | -0.17 | -19.16% |
| Nov 6, 2025 | Sep 30, 2025 | 0.77 | 0.93 | +0.16 | +20.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Aug 18, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Aug 7, 2026 | Piper Sandler | main | Neutral | Neutral |
| Aug 7, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Jun 29, 2026 | B of A Securities | down | Neutral | Underperform |
| Jun 3, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- amphastar.com
News
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $25
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Amphastar Pharmaceuticals Q3 Earnings Call Highlights
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates Amphastar Pharma Q3 Adj. EPS $1.14 Beats $0.86 Estimate, Sales $207.608M Beat $197.852M Estimate
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
Your note
Sign in to keep a note on AMPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEFLIN GAYLE | Director | Stock Award(Grant) | May 31, 2026 | 19,057 |
| GERST DIANE G. | Director | Stock Award(Grant) | May 31, 2026 | 31,899 |
| LEE HOWARD S | Director | Stock Award(Grant) | May 31, 2026 | 159,350 |
| LIAWATIDEWI YAKOB | Officer and Director | Stock Award(Grant) | Mar 8, 2026 | 125,384 |
| PETERS WILLIAM J | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 15, 2026 | 167,076 |
| PETERSEN FLOYD F | Director | Sale | Dec 11, 2025 | 71,368 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.00% | 5,118,737 | 143.89M | Sep 29, 2026 |
| Dimensional Fund Advisors LP | 5.59% | 2,382,991 | 66.99M | Sep 29, 2026 |
| State Street Corporation | 3.92% | 1,674,060 | 47.06M | Sep 29, 2026 |
| American Century Companies Inc | 3.72% | 1,585,068 | 44.56M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 2.91% | 1,239,347 | 34.84M | Sep 29, 2026 |
| Marshall Wace LLP | 2.85% | 1,216,253 | 34.19M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.39% | 1,873,133 | 52.65M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.06% | 1,303,435 | 36.64M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.48% | 1,055,676 | 29.68M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund | 2.12% | 902,737 | 25.38M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.97% | 839,366 | 23.59M | Sep 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 1.40% | 596,077 | 16.76M | Jul 30, 2026 |
